Novartis Investigative Site

Bron, Cedex 69677

0 studies enrolling now · 2 studies all time

What they study most

Acromegaly, Heart Failure With Reduced Ejection Fraction (HF-rEF)

Studies at this site

• Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF) — NO_LONGER_AVAILABLE
• Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly — Completed